Global X HealthTech ETF (NASDAQ:HEAL – Get Free Report) was the target of a significant decrease in short interest in October. As of October 15th, there was short interest totaling 1,958 shares, a decrease of 45.6% from the September 30th total of 3,598 shares. Currently, 0.2% of the shares of the stock are short sold. Based on an average daily volume of 4,540 shares, the short-interest ratio is presently 0.4 days.
Institutional Inflows and Outflows
Institutional investors have recently modified their holdings of the stock. C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors boosted its holdings in Global X HealthTech ETF by 28.3% in the 3rd quarter. C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors now owns 195,122 shares of the company’s stock valued at $5,758,000 after purchasing an additional 43,075 shares during the last quarter. Farther Finance Advisors LLC lifted its holdings in Global X HealthTech ETF by 4.3% in the third quarter. Farther Finance Advisors LLC now owns 23,037 shares of the company’s stock valued at $680,000 after acquiring an additional 950 shares during the last quarter. Finally, Royal Bank of Canada grew its position in Global X HealthTech ETF by 39.4% in the first quarter. Royal Bank of Canada now owns 2,603 shares of the company’s stock worth $62,000 after acquiring an additional 736 shares during the period.
Global X HealthTech ETF Trading Up 0.2%
NASDAQ HEAL traded up $0.06 on Monday, reaching $30.76. 3,343 shares of the company were exchanged, compared to its average volume of 10,480. The business’s fifty day moving average price is $29.69 and its 200 day moving average price is $27.31. The stock has a market capitalization of $34.76 million, a P/E ratio of 42.80 and a beta of 1.13. Global X HealthTech ETF has a fifty-two week low of $23.00 and a fifty-two week high of $32.15.
About Global X HealthTech ETF
An ETF that invests in companies at the intersection of healthcare and technology, targeting innovations in drug discovery, medical devices, consumer healthcare, and analytics.
See Also
- Five stocks we like better than Global X HealthTech ETF
- AbbVie’s Humira Era Is Fading, But Its New Growth Engines Face Another Test
- GLP-1 Focus or Broader Peptide Exposure: Which ETF Has the Edge?
- Mortgage Rates Froze U.S. Housing, But These 3 Overseas Markets Still Pay Double Digits
- Big Tech Is Spending Billions on AI—These 5 Stocks Are Getting Paid
Receive News & Ratings for Global X HealthTech ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Global X HealthTech ETF and related companies with MarketBeat.com's FREE daily email newsletter.
